坦索罗辛胶囊联合益气活血方治疗经皮肾镜超声弹道碎石术后肾损伤的临床研究
发布时间：2018-11-22 14:53
【摘要】：目的观察坦索罗辛胶囊联合益气活血方治疗经皮肾镜超声弹道碎石术后肾损伤的临床疗效及安全性。方法将52例经皮肾镜超声弹道碎石术后肾损伤患者随机分为对照组26例与试验组26例。对照组予以口服盐酸坦索罗辛缓释胶囊每次0.4 mg,qd;试验组在对照组治疗的基础上,予以口服益气活血方每次100 m L,早晚各一次。2组患者均治疗28 d。比较2组患者的临床疗效、血清胱抑素C(Cys-C)、肾损伤分子1(Kim~(~(-1)))、24 h尿蛋白定量(24 h Up)、血尿酸(UA)、血清肌酸酐(SCr)、尿素氮(BUN)水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为84.62%(22/26例)和57.69%(15/26例),差异有统计学意义(P0.05)。治疗后,试验组和对照组的Cys-C分别为(1.65±0.27),(2.01±0.29)mg·L~(~(-1));Kim~(~(-1))分别为(31.38±3.76),(39.02±4.88)pg·m L~(~(-1));24 h Up分别为(0.52±0.07),(0.81±0.10)g·d~(~(-1));UA分别为(428.07±50.39),(468.93±52.26)μmol·L~(~(-1));SCr分别为(329.02±40.11),(398.02±45.44)μmol·L~(~(-1));BUN分别为(14.09±1.78),(18.00±2.44)mmol·L~(~(-1)),差异均有统计学意义(均P0.05)。试验组的药物不良反应主要有头痛、腹泻和手足皮肤反应,对照组的药物不良反应主要有头痛、高血压和腹泻。试验组和对照组的药物不良反应发生率分别为11.54%和15.38%,差异无统计学意义(P0.05)。结论坦索罗辛胶囊联合益气活血方治疗经皮肾镜超声弹道碎石术后肾损伤的临床疗效显著,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the clinical efficacy and safety of tansoloxin capsule combined with Yiqi Huoxue recipe in the treatment of renal injury after percutaneous nephroscopic ultrasound ballistic lithotripsy. Methods 52 patients with renal injury after percutaneous nephroscopic ultrasound lithotripsy were randomly divided into control group (n = 26) and experimental group (n = 26). The control group was administered orally with tansoloxine hydrochloride sustained release capsule each time. On the basis of the treatment in the control group, 100ml of Yiqi Huoxue prescription was given orally, once in the morning and evening. The patients in both groups were treated for 28 days. The clinical efficacy, serum cystatin C (Cys-C), renal injury molecule 1 (Kim~ (-1), 24 h urinary protein quantification (24 h Up), serum creatinine (SCr),) were compared between the two groups. Urea nitrogen (BUN) levels and adverse drug reactions. Results after treatment, the total effective rates of the experimental group and the control group were 84.62% (22 / 26 cases) and 57.69% (15 / 26 cases), respectively. The difference was statistically significant (P0.05). After treatment, the Cys-C of the trial group and the control group were (1.65 卤0.27), (2.01 卤0.29) mg L ~ (-1);, respectively. Kim~ (-1) were (31.38 卤3.76), () 39.02 卤4.88) pg m L-1); 24 h Up (0.52 卤0.07), (0.81 卤0.10) g d-1);, respectively. UA was (428.07 卤50.39), (468.93 卤52.26) 渭 mol L ~ (-1); SCr (329.02 卤40.11), (398.02 卤45.44) 渭 mol L ~ (-1);, respectively. BUN was (14.09 卤1.78), (18.00 卤2.44) mmol L ~ (-1), (P0.05). The main adverse drug reactions in the trial group were headache, diarrhea and skin reaction of the hands and feet, and the adverse drug reactions in the control group were headache, hypertension and diarrhea. The incidence of adverse drug reactions in experimental group and control group were 11.54% and 15.38%, respectively, with no significant difference (P0.05). Conclusion the clinical effect of tansoloxin capsule combined with Yiqi Huoxue recipe in treating renal injury after percutaneous nephroscopic ultrasound ballistic lithotripsy is significant and the incidence of adverse drug reaction is not increased.
【作者单位】： 海南省农垦那大医院泌尿外科;
【基金】：国家医学教育发展中心医学研究课题基金资助项目(2010-37-03-004)
【分类号】：R699
，
本文编号：2349686
[Abstract]:Objective to observe the clinical efficacy and safety of tansoloxin capsule combined with Yiqi Huoxue recipe in the treatment of renal injury after percutaneous nephroscopic ultrasound ballistic lithotripsy. Methods 52 patients with renal injury after percutaneous nephroscopic ultrasound lithotripsy were randomly divided into control group (n = 26) and experimental group (n = 26). The control group was administered orally with tansoloxine hydrochloride sustained release capsule each time. On the basis of the treatment in the control group, 100ml of Yiqi Huoxue prescription was given orally, once in the morning and evening. The patients in both groups were treated for 28 days. The clinical efficacy, serum cystatin C (Cys-C), renal injury molecule 1 (Kim~ (-1), 24 h urinary protein quantification (24 h Up), serum creatinine (SCr),) were compared between the two groups. Urea nitrogen (BUN) levels and adverse drug reactions. Results after treatment, the total effective rates of the experimental group and the control group were 84.62% (22 / 26 cases) and 57.69% (15 / 26 cases), respectively. The difference was statistically significant (P0.05). After treatment, the Cys-C of the trial group and the control group were (1.65 卤0.27), (2.01 卤0.29) mg L ~ (-1);, respectively. Kim~ (-1) were (31.38 卤3.76), () 39.02 卤4.88) pg m L-1); 24 h Up (0.52 卤0.07), (0.81 卤0.10) g d-1);, respectively. UA was (428.07 卤50.39), (468.93 卤52.26) 渭 mol L ~ (-1); SCr (329.02 卤40.11), (398.02 卤45.44) 渭 mol L ~ (-1);, respectively. BUN was (14.09 卤1.78), (18.00 卤2.44) mmol L ~ (-1), (P0.05). The main adverse drug reactions in the trial group were headache, diarrhea and skin reaction of the hands and feet, and the adverse drug reactions in the control group were headache, hypertension and diarrhea. The incidence of adverse drug reactions in experimental group and control group were 11.54% and 15.38%, respectively, with no significant difference (P0.05). Conclusion the clinical effect of tansoloxin capsule combined with Yiqi Huoxue recipe in treating renal injury after percutaneous nephroscopic ultrasound ballistic lithotripsy is significant and the incidence of adverse drug reaction is not increased.
【作者单位】： 海南省农垦那大医院泌尿外科;
【基金】：国家医学教育发展中心医学研究课题基金资助项目(2010-37-03-004)
【分类号】：R699
，
本文编号：2349686
本文链接：https://www.wllwen.com/yixuelunwen/mjlw/2349686.html
最近更新
教材专著
